About 100 scientists, researchers, pharmaceutical executives, and others will converge on Austria’s capital city early next month for the 2nd International Congress on Advanced Treatments in Rare Diseases. The March 4-5 meeting, to take place at the Hilton Am Stadtpark Vienna, features 27 speakers on a variety of disorders…
News
Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities aim to raise awareness about rare diseases and the millions of people — estimates run as high as 350 million — they are thought to impact. Across countries, patients, caregivers and advocates will paint faces, wear…
Once-monthly injections of givosiran can safely reduce the rate of recurrent porphyria attacks by effectively reducing disease-triggering neurotoxic compounds, data from a Phase 1 clinical trial suggests. The trial findings were reported in a study, “Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent…
The U.S. Food and Drug Administration(FDA) is updating its 2015 draft guidelines for drug discovery in rare diseases, with new guidance on natural history— how disorders such as spinal muscle atrophy(SMA) run their course if untreated — the choice of “efficacy endpoints” in clinical trials, and how…
Researchers described the case of a Japanese patient with familial porphyria cutanea tarda (PCT) carrying a previously unreported mutation in the UROD gene. The case report, “The first Japanese case of familial porphyria cutanea tarda diagnosed by a UROD mutation,” appeared in the Journal…
Differential responses to blood vessel contraction and widening may underlie hypertension in patients experiencing acute intermittent porphyria (AIP) attacks, according to a mouse study. In addition, the differences found between male and female mice in the study may help explain the greater incidence of AIP attacks in women. The study,…
The antiviral combo therapy of ribavirin and sofosbuvir successfully cleared a patient’s hepatitis C virus and led to remission of his porphyria cutanea tarda (PCT), a case study reports. The study, “Improvement of porphyria cutanea tarda following treatment of hepatitis C virus by direct-acting antivirals: A case…
High energy intake and insulin levels, as well as increased sugar and candy consumption, are associated with lower disease activity in acute intermittent porphyria, a small population-based study suggests. The study, “Lifestyle factors including diet and biochemical biomarkers in acute intermittent porphyria: Results from a case-control study…
The ClpX protein recently has been studied for its role in causing erythropoietic protoporphyria (EPP). In a review study, researchers explored this connection and recommended further genetic studies. The study, “The role of ClpX in erythropoietic protoporphyria,” was published in the journal Hematology, Transfusion and Cell Therapy.
News
19 New Mutations Identified in Patients with Hereditary Forms of Porphyria, Including PCT Type 2
A genetic study found 19 new mutations in the…
Recent Posts
- Disappointed by the FDA’s ruling on an investigational EPP treatment
- The importance of being able to explain our porphyria symptoms
- Unexplained abdominal pain and low sodium reveal AHP diagnosis
- FDA denies accelerated approval of bitopertin, awaits trial results
- Mouse study: Genes, diet may shape risk for common porphyria
- Claw-like hands revealed hidden nerve damage in woman with AIP
- Being a blessed porphyria warrior is about more than just a slogan
- New EPP drug candidates hard to compare with Scenesse, analysis finds
- New trial results show bitopertin eases a major driver of EPP symptoms